Published Date: 30-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global PEGylated Proteins Market size is expected to reach $2.1 billion by 2028, rising at a market growth of 11.3% CAGR during the forecast period.
The Consumables segment is leading the Global PEGylated Proteins Market by Product & Services in 2021 thereby, achieving a market value of $1.4 billion by 2028. Usage of PEGylating consumables, including kits and reagents, is constant due to ongoing research activities, product advancements, and the desire to create better medications and drug delivery methods, which leads to substantial revenue generation. A further factor driving segment expansion is the existence of big players with a wide range of product offerings.
The Colony-stimulating Factor segment is showcasing a CAGR of 10.6 % during (2022 - 2028). Hematopoietic stem cells are stimulated to proliferate and differentiate into white blood cells by growth factors called CSFs, which bind to receptor proteins (WBCs). CSFs are utilized as a pharmacological drug to boost immune function in cancer patients who are at risk for infection because of neutropenia (low WBCs).
The Pharmaceutical & Biotechnology Companies segment acquired maximum revue share in the Global PEGylated Proteins Market by End-user in 2021 thereby, achieving a market value of $967.8 million by 2028. Due to numerous medication research and development programs, increasing R&D funding, and helpful government actions, there are now more therapeutic products in the pipeline. Additionally, the regulatory support for new product approvals demonstrates the industry dominance of pharmaceutical and biotechnology firms.
The Autoimmune Diseases segment has shown the growth rate of 11.1% during (2022 - 2028). The growth and development of PEGylated Proteins are directly impacted by the rise in the occurrence of autoimmune disorders. The prevalence of disorders such as systemic lupus erythematosus, rheumatoid arthritis, Hashimoto's thyroiditis, Graves' disease, and type 1 diabetes is expected to rise, which will propel the market's growth.
The North America market dominated the Global PEGylated Proteins Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $739 million by 2028.The Asia Pacific market is poised to grow at a CAGR of 12.1% during (2022 - 2028). Additionally, The Europe market would witness a CAGR of 10.9% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck Millipore (Merck KGaA), Thermo Fisher Scientific, Inc., NOF Corporation, JenKem Technology Co. Ltd., Creative PEGworks, Celares GmbH, Quanta BioDesign, Ltd., Biomatrik, Inc., Iris Biotech GmbH, and Laysan Bio, Inc.
By Product & Services
Unique Offerings from KBV Research